
==== Front
J Agric Food Chem
J Agric Food Chem
jf
jafcau
Journal of Agricultural and Food Chemistry
0021-8561
1520-5118
American Chemical Society

39214666
10.1021/acs.jafc.4c04849
Article
Preparation and Preclinical Characterization of a Simple Ester for Dual Exogenous Supply of Lactate and Beta-hydroxybutyrate
Ottosen Rasmus N. †
Seefeldt Jacob M. ‡
Hansen Jakob §
Nielsen Roni ‡
Møller Niels *∥⊥
Johannsen Mogens *§
https://orcid.org/0000-0002-0763-9996
Poulsen Thomas B. *†
† Department of Chemistry, Aarhus University, Langelandsgade 140, Aarhus C DK-8000, Denmark
‡ Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N DK-8200, Denmark
§ Department of Forensic Medicine, Aarhus University, Palle Juul-Jensens Boulevard. 99, Aarhus N DK-8200, Denmark
∥ Steno Diabetes Center Aarhus, Aarhus University Hospital, Palle Juul-Jensens Boulevard 11, Aarhus N DK-8200, Denmark
⊥ Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, Aarhus N DK-8200, Denmark
* Email: niels.moeller@clin.au.dk.
* Email: mj@forens.au.dk.
* Email: thpou@chem.au.dk.
30 08 2024
11 09 2024
72 36 1988319890
02 06 2024
15 08 2024
15 08 2024
© 2024 The Authors. Published by American Chemical Society
2024
The Authors
https://creativecommons.org/licenses/by/4.0/ Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).

Elevation of the plasma levels of (S)-lactate (Lac) and/or (R)-beta-hydroxybutyrate (BHB) occurs naturally in response to strenuous exercise and prolonged fasting, respectively, resulting in millimolar concentrations of these two metabolites. It is increasingly appreciated that Lac and BHB have wide-ranging beneficial physiological effects, suggesting that novel nutritional solutions, compatible with high-level and/or sustained consumption, which allow direct control of plasma levels of Lac and BHB, are of strong interest. In this study, we present a molecular hybrid between (S)-lactate and the BHB-precursor (R)-1,3-butanediol in the form of a simple ester referred to as LaKe. We show that LaKe can be readily prepared on the kilogram scale and undergoes rapid hydrolytic conversion under a variety of physiological conditions to release its two constituents. Oral ingestion of LaKe, in rats, resulted in dose-dependent elevation of plasma levels of Lac and BHB triggering expected physiological responses such as reduced lipolysis and elevation of the appetite-suppressing compound N-L-lactoyl-phenylalanine (Lac-Phe).

lactate
ketones
exercise mimetics
exerkine
N-L-lactoyl-phenylalanine (Lac-Phe)
appetite regulation
Novo Nordisk Fonden 10.13039/501100009708 NNF19OC0054782 Novo Nordisk Fonden 10.13039/501100009708 NNF21OC0069002 document-id-old-9jf4c04849
document-id-new-14jf4c04849
ccc-price
==== Body
pmcIntroduction

Exercise is, together with caloric restriction, widely recognized as the most powerful intervention increasing healthy lifespan by preserving muscle mass and cognitive functions. Extensive research efforts have been dedicated to unraveling the physiological response triggered by exercise, with a particular focus on identifying the metabolic drivers behind its adaptive and protective effects.1−5 Among the noteworthy findings, a remarkable surge in circulating lactate levels has been observed, transitioning from micromolar to millimolar within minutes of engaging in physical activity.6,7

Traditionally regarded as a metabolic waste product, lactate, a small alpha-hydroxylated organic acid, has recently emerged as a significant mitochondrial fuel and circulating messenger.8,9 This shift in understanding has been facilitated by the discovery of its interaction with G-protein-coupled receptor HCAR1, along with various alternative signaling mechanisms. Consequently, it is now hypothesized that lactate may serve as a key exerkine,10−12 mediating numerous physiological effects of exercise on human physiology.4,12−16

Supporting this hypothesis, a multitude of preclinical and clinical investigations have demonstrated that exogenous lactate administration elicits biological responses comparable to those observed during exercise. Such responses include the elevation of crucial hormones, such as BDNF, VEGF, LEAP2, GLP-1, Lac-Phe, as well as other significant physiological reactions.16−23

In parallel, ketone bodies, beta-hydroxybutyrate (BHB) and acetoacetate, exhibit a noteworthy increase from micromolar to millimolar levels during exercise, albeit at a more modest pace as glycogen stores are depleted.6,24 During caloric restriction or fasting, ketones rise to a similar extent.25 Similar to lactate, ketone bodies were also traditionally considered undesired metabolic byproducts, although by now, it is well-established that they not only serve as excellent mitochondrial fuels but also function as vital cellular messengers. Their signaling occurs through the distinctive G-protein-coupled receptor HCAR2, along with alternative mechanisms, thereby impacting positively on a number of aging-related diseases.25−29 Clinical studies employing exogenous ketone esters or salts have substantiated their efficacy in inducing these effects.30−32

Intriguingly, a number of preclinical and clinical trials have reported strikingly beneficial effects of both lactate and ketones on, for example, cardiac performance20,32,33 and appetite regulation,21,22,34 suggesting a possibility for additive or synergistic effects of the two compounds in tandem. Such aspects are perhaps particularly compelling in brain aging and disease.35,36 This is supported by a high number of preclinical studies demonstrating how exogenous lactate appears to favorably impact brain homeostasis and depression,37 an effect potentially mediated via stimulation of neurogenesis/angiogenesis.19,38−43 Ketone bodies, in comparison, seem to exert neuroprotective effects and thereby stimulating cognitive functions.44−46

Consequently, there is growing interest in the development of new nutritional solutions that enable safe, dual supplementation of lactate and beta-hydroxybutyrate (BHB)/acetoacetate (AcAcO). Ideally, this would involve structurally simple and orally bioavailable compounds that can efficiently release both metabolites, or their direct precursors, while being devoid of any additional byproducts, thereby allowing long-term consumption.

Materials and Methods

Synthesis Chemistry: General Methods

Reactions were conducted in flame-dried glassware under an atmosphere of dry argon, unless otherwise stated. THF was dried over aluminum oxide via an MBraun SPS-800 solvent purification system. MeOH and DMF was purchased as anhydrous and further dried and stored under argon over activated molecular sieves (4 Å). The dryness of the solvents was controlled via Karl Fischer titration. Other reagents were used as received from commercial suppliers, unless otherwise stated. DIPEA was dried by stirring for at least 30 min over CaH2 followed by distillation onto preactivated molecular sieves (4 Å). Concentration in vacuo was performed using a rotary evaporator with the water bath temperature at 35 °C, followed by further concentration using a high vacuum pump. TLC analysis was carried out on silica-coated aluminum foil plates (Merck Kieselgel 60 F254). The TLC plates were visualized by UV irradiation and/or by staining with KMnO4 stain (KMnO4 (5.0 g), 5% NaOH (aq., 8.3 mL), and K2CO3 (33.3 g) in H2O (500 mL)). Molecular sieves were activated by drying in the oven at 120 °C for at least 24 h, before they were heated in a microwave at maximum power for 2 min, followed by evaporation of the formed vapor on a high vacuum line. This was repeated three to four times and finished by gently flame-drying the flask containing the molecular sieves. Automated flash column chromatography (AFCC) was carried out with an Interchim PuriFlash 420 or Interchim PuriFlash 5.050 using 30 μm prepacked columns. Mass spectra (HRMS) were recorded on a Bruker Daltonics MicrOTOF time-of-flight spectrometer with positive electrospray ionization. Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Mercury 400 MHz spectrometer running at 400 and 101 MHz for 1H and 13C, respectively. Chemical shifts (δ) are reported in ppm relative to the residual solvent signals (CDCl3: 7.26 ppm 1H NMR, 77.16 ppm 13C NMR, etc.). Multiplicities are indicated using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, h = heptet, and m = multiplet.

For remaining methods (all synthetic procedures and characterization data), see the Supporting Information.

Stability of LaKe upon Storage

This experiment was carried out at NCK A/S.

Following preparation, LaKe was analyzed by GC-FID. Subsequently, LaKe was stored neat at either −15, 0, and 20 °C and the samples were reanalyzed after 24 months. Table S1 (Supporting Information) contains the corresponding stability data and the GC-FID conditions applied.

In Vitro Stability of LaKe

These experiments were carried out at Wuxi AppTec.

The in vitro stability of LaKe was evaluated following incubation in simulated gastric fluid (SGF), simulated intestinal fluid (SIF), fresh and frozen plasma (rats and humans, respectively), and the presence of hepatocytes (rats and humans) and liver microsomes (rats and humans). At the chosen time points, the mixtures were analyzed by LC-MS/MS to quantify the remaining LaKe and all assays included at least one control compound with known pharmacokinetic properties.

For detailed procedures for these experiments, see the Supporting Information.

Short-Term Pharmacokinetics of LaKe in Rats

This method was used to generate the data presented in Figures 6 and 8.

Male Sprague–Dawley rats (300–350g, Taconic, Ry, Denmark) were kept for acclimatization at a constant temperature of 23 °C with a 12 h light-dark cycle and with unlimited access to food and water. All animal handling was in accordance with national guidelines in Denmark and the guidelines from the Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes, and all experiments conformed to Danish Law (Act. No. 1306 of 23/11/2007). The experimental protocol was approved by the Danish Animal Expectorate (2018-15-0201-01475).

The rats were randomly selected to receive either LaKe (n = 8) or placebo (n = 8).

Rats were anesthetized in an induction chamber with 8% Sevoflurane (Sevorane, AbbVIE A/S, Copenhagen, Denmark) mixed with oxygen saturated atmospheric air (flow: 2.0 L/min). Upon achieved anesthesia, the rats were intubated and connected to a mechanical ventilator (Ugo Basile 7025 rodent ventilator, Comerio, Varese, Italy) with an adjusted flow of 1.0L/min with 3.5% Sevoflurane. Body temperature was kept at a constant of 37 ± 1 °C with a temperature probe (UNO, Zevenaar, Holland). A PTFE-coated flexible orogastric tube (Fuchigami, Japan) was placed, and the rat was left for stabilization for 15 min.

After stabilization, a baseline blood sample was collected from the rat tail vein before administration of LaKe or placebo. LaKe was diluted in physiological saline solution (0.9% NaCl) and administered as a single bolus of 2 mL, per oral dose (4500 mg/kg). Placebo animals received a single bolus of 2 mL of physiological saline solution (0.9% NaCl). Following the baseline blood sample, a bolus of LaKe-solution or placebo was administered via the orogastric tube to the animals. Every 15 min for a period of 2 h, blood samples (200 μL each) were collected in microvettes (sarstedt, 20.1280.100) and were left to coagulate for 30 min followed by centrifugation at 4 and 1500 °C for 20 min. Serum was collected and stored at −80 °C for further analysis by LC-MS/MS (BHB, lactate, and N-L-lactoyl phenylalanine (Lac-Phe)) and for nonesterified free fatty acids (FFA).

For detailed procedures for LC-MS/MS and FFA analyses, see the Supporting Information.

Statistical Analyses

Data are expressed as mean ± SD unless otherwise specified. P-values <0.05 were considered statistically significant. Based on our own experience and reports by other research groups, a sample size of minimum N = 6 was considered adequate to identify a treatment effect, unless specifically stated. Experiments were performed with parallel administration of intervention and control solutions to eliminate potential time effects. Rats were randomly selected to receive either LaKe or the control solutions. The effect of two categorial variables, time and randomization group, on a dependent variable (plasma concentration of selected metabolites) was evaluated using a mixed-effect model for repeated measures. Bonferroni’s correction was applied for multiple comparisons. All analyses were performed using GraphPad Prism 8.2.0 (Graph Pad Software, CA, USA).

Extended Pharmacokinetics of LaKe in Rats

This experiment was carried out at Wuxi AppTec. This method was used to generate the data presented in Figure 7.

Animals (SD rats, both male and female, 7–9 weeks) were individually housed from 24 h before dosing until the end of the study. Food was withdrawn the night before initiation of study; following food withdrawal, animals were maintained on glucose water containing 5% w/v glucose and 1% saline to suppress endogenous ketone production throughout the study. Food was returned 8 h post-test article dosing. Animals were monitored for distress or notable changes in behavior during the study. The animals were euthanized by CO2 inhalation 2 h after the last sample collection time point.

Blood collection was performed by jugular vein cannulation of each animal and divided into two parts. About 10–15 μL of blood was used for the analysis of glucose by glucometer measurement. About 0.20 mL of blood was collected into prechilled commercial EDTA-K2 tubes containing 5 μL of the esterase inhibitor (100 mM PMSF in ethanol, 40 mg/mL NaF and 120 mg/mL KO in water = 5:95(v/v). All blood samples were placed on wet ice until centrifugation.

At least 100 μL plasma was collected respectively and transferred into polypropylene tubes with 400 mM TTFA (2-thenoyltrifluoroacetone) in ethanol (plasma:stabilizer = 100:5 (v:v)). The final concentration of TTFA in the plasma sample from each time point was approximately 20 mM. The samples were snap frozen over dry ice and kept at −60 °C or lower until LC-MS/MS analysis for 3-hydroxybutyl 2-hydroxypropanoate (LaKe), lactate, and β-hydroxybutyrate (BHB).

For detailed procedures for LC-MS/MS-analyses, see the Supporting Information.

Results and Discussion

Design of LaKe

We considered several different designs to achieve dual oral delivery of lactate and BHB and identified the primary carboxylic ester of (S)-lactate and (R)-1,3-butanediol as possibly the simplest solution (Figure 1). We hypothesized that this molecule, which we refer to as LaKe, would be hydrolytically cleaved, either upon exposure to pH extremes or, more likely, via the enzymatic activity of hydrolases (lipases) that are abundant in the gastrointestinal tract and in plasma. Hydrolysis of the ester bond would liberate (S)-lactate and (R)-1,3-butanediol directly, the latter being a well-known precursor for BHB/AcAcO following oxidation in the liver (Figure 1).47 The release of these two molecules were particularly appealing from a safety perspective: (S)-lactate is a natural metabolite and (R)-1,3-butanediol is generally recognized as safe (GRAS)48 for large-scale human ingestion and the same building block also features in the design of pure ketone esters, such as (R)-3-hydroxybutyl (R)-3-hydroxybutyrate47 and bis-hexanoyl (R)-1,3-butanediol.49 By formation of the (neutral) ester, the use of salt-forms is bypassed. This is a critical parameter as continuous ingestion of large quantities of, for example, the sodium or potassium salts of (S)-lactate and (R)-BHB/AcAcO risk exceeding the safe dose recommended by authorities and may cause electrolyte imbalances and gastrointestinal side-effects.50 Such concerns would be even more pronounced in weakened individuals and people with reduced organ function, for example, of the kidneys. We also considered hybrid lactate-ketone designs featuring different smaller oligomers of lactate (as polylactate is a biocompatible polymer); however, the resulting congested esters might be subject to much slower hydrolysis and thereby induce elevated plasma concentrations of synthetic compounds with unknown properties or long-term effects. In conclusion, LaKe seemed like an optimal and simple design, subjected to the conditions that the compound could be readily prepared on large scale and that it would be rapidly converted to its constituents.

Figure 1 Design of LaKe. A simple, neutral ester that allows hydrolytic release of (S)-lactate and, following subsequent oxidation, (R)-beta-hydroxybutyrate (BHB).

Chemical and Chemoenzymatic Synthesis of LaKe

We first developed a short chemical synthesis of the structure (Figure 2). Toward this end, we started with commercially available ethyl (S)-lactate. Following standard protection of the secondary hydroxyl group as a tert-butyldimethylsilyl (TBS) ether, the ester was hydrolyzed in the presence of aqueous sodium hydroxide solution. The resulting acid (1) was subjected to ester coupling with (R)-1,3-butanediol to selectively afford primary ester 2. Finally, we removed the TBS group and, following some experimentation, found that this was best accomplished in the presence of the weak acid KHSO4 in a mixed solvent system. We used normal column chromatography on silica gel to purify the compound, which by NMR analysis was found to comprise a 10/1 mixture of the primary (3) and secondary (4) ester. Given the obvious ability of 3 and 4 to interconvert via an intramolecular transesterification (vide infra), we speculated that some degree of equilibration occurred during the deprotection or subsequent purification. Subsequently, we refer to any mixture of 3 and 4 as LaKe. Our synthesis could readily deliver LaKe on a multigram scale. Furthermore, we also demonstrated that the same overall sequence could be used to afford a stereochemical isomer made from (R)-lactate and (R)-1,3-butanediol (see the Supporting Information), thereby offering an alternative possibility for delivery of (R)-lactate. Indeed, this overall sequence is compatible with any stereoisomeric form and, thereby, also with racemic starting materials.

Figure 2 Gram-scale, chemical synthesis of LaKe from ethyl (S)-lactate and (R)-1,3-butanediol. Reagents and conditions: (a) TBSCl (1.5 equiv), imidazole (3.5 equiv), DMF, rt, 3 h; (b) LiOH (0.5 M aq., 2.0 equiv), THF, 0 °C to rt, 5 h; (c) TBTU (1.5 equiv), DIPEA (2.1 equiv), DMF, rt, 1 h then (R)-1,3-butanediol (1.0 equiv), rt, 16 h; (d) KHSO4 (0.25 equiv), THF/H2O/MeOH (10/10/4), rt, 16 h. Abbreviations: TBTU = 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate; TBS = tert-butyldimethylsilyl; DIPEA = N,N-diisopropylethylamine; THF = tetrahydrofuran.

Next, we sought to simplify the approach substantially. Lipase enzymes are known to catalyze transesterification reactions with high efficiency.51 We therefore evaluated whether direct, single-step preparation of LaKe could be performed from ethyl (S)-lactate and (R)-1,3-butanediol. Indeed, following optimization of several parameters, we were able to conduct a very efficient synthesis in the presence of immobilized Novozym 435 with 5 equiv of ethyl (S)-lactate. This process was readily scalable, and through final purification by distillation, we prepared 6.3 kg corresponding to a 63% yield (Figure 3).

Figure 3 Kilogram-scale, chemoenzymatic synthesis of LaKe.

As in the case of the chemical synthesis, we again observed a mixture (5/1) of 3 and 4. Systematic study showed that 3 was the exclusive product directly following the synthesis; however, by heating the sample in relation to the distillation (115 °C) or by further heating (135 °C), the ratio of 3 to 4 approaches 3/1 (Figure 4). All in all, we developed different synthetic methods to access LaKe. The chemoenzymatic approach is operationally extremely simple, allowing us to readily proceed to kilogram scale. The compound showed stability to storage in the neat state for at least 2 years at ambient temperature (Table S1, Supporting Information).

Figure 4 Chemical equilibrium between primary ester (3) and secondary ester (4).

In Vitro Pharmacokinetics of LaKe

We evaluated the stability of LaKe under a variety of different conditions (Figure 5). While the compound does undergo conversion under conditions simulating the environment of the stomach (SGF, pH = 1), it was not very rapid (T1/2 > 12 h). Much faster conversion (T1/2 < 2 h) was observed in the presence of intestinal enzymes (pancreatin, SIF) at pH = 6.8. This supported the initial hypothesis concerning the expected behavior of the compound in vivo. Further consolidation was provided by observation of very fast turnover in both human and rat hepatocytes and plasma (T1/2 < 30 min). Indeed, in fresh plasma from rats, LaKe could not be detected at the first time point, 10 min. The compound also underwent turnover in both rat and human liver microsomes albeit somewhat slower. The data displayed in Figure 5 were performed in the presence of NADPH; however, conversion also occurred in the absence of activating NADPH with 82% (human) and 55% (rat) LaKe remaining after 60 min. All in all, the results suggest that LaKe will undergo rapid, enzyme-mediated, hydrolytic turnover in vivo to release its constituents, (S)-lactate and (R)-1,3-butanediol.

Figure 5 In vitro pharmacokinetics of LaKe. SIF = simulated intestinal fluid. SGF = simulated gastric fluid. SIF/SGF data are mean ± SD (N = 2). Hepatocyte data are mean ± SD (N = 2). Microsome and plasma data are mean (N = 2).

In Vivo Pharmacokinetics of LaKe

Next, we conducted an experiment involving acute, oral administration of 4.5 g/kg LaKe to Sprague–Dawley rats and monitored the plasma concentrations of lactate and BHB, respectively, by blood sampling every 15 min until 120 min (Figure 6). To minimize eventual stress-induced changes in metabolite levels, the rats were anesthetized during the experiment and allowed to stabilize for 15 min after instrumentation. During 15 min, following LaKe dosing, the average plasma concentration of BHB increased from a baseline value of about 0.2–1.1 mM and reached a peak level of 2.0 mM after 105 min. Likewise, plasma levels of lactate also increased rapidly from the baseline (ca. 4 mM) to a peak level of 9.0 mM after 30 min. At 120 min, lactate levels were largely back at the baseline level, whereas BHB levels remained elevated. This experiment clearly demonstrated that oral administration of LaKe could elevate lactate and BHB levels in vivo. The pharmacokinetic profile observed is compatible with the rapid release of lactate following hydrolysis and slower formation of BHB from oxidation of 1,3-butanediol.

Figure 6 Short-term pharmacokinetics following oral administration of LaKe in rats. Data are mean ± SD (N = 8). ns = nonsignificant; * P < 0.05; ** P < 0.01; *** P < 0.001.

Encouraged by these results, we next conducted an additional experiment in rats to evaluate both an extended pharmacokinetic profile (8 h) and different doses of LaKe (up to 12 g/kg). Before administration of LaKe, the rats were fasted overnight and maintained on glucose-water to suppress endogenous ketone body and additional lactate formation. In this experiment, the rats were not anesthetized. Again, we observed clear, dose-dependent elevation of plasma levels of both BHB and lactate. The concentrations of BHB remain within a window of 0.5 mM to about 2 mM (corresponding to ca. 5–20 fold increase over baseline) with increasing doses resulting in an extended duration of the induced ketosis (Figure 7). Like the first experiment, lactate levels display a somewhat faster return to baseline values, with peak levels corresponding to approximately 4-fold increase compared to baseline values in the first 2 h at both the low and intermediate doses, the latter with an extended duration (Figure 7). At the high dose, plasma levels of lactate in this experiment reached 10 mM and remained elevated at the final time point (8 h). At the 4.1 g/kg dose, the average area under the curve (AUC) of each metabolite, following subtraction of AUC of vehicle, was similar (lactate: 5233 μM·h, BHB: 5563 μM·h) in accordance with the 1:1 stoichiometry. With respect to blood glucose, we observed a nonsignificant trend toward lower glucose levels with high-dose LaKe exposure (Figure 7). It should be noted that our study design involved continuous ingestion of 5% glucose water, which per se probably affected these results by increasing insulin levels and decreasing free fatty acid levels (Figure 7). We also assessed the plasma concentrations of LaKe at the low and high concentration. Encouragingly, even at the maximum dose of 12 g/kg, average plasma levels of LaKe reached a maximum of just 5 μM. At the lower dose, LaKe was only detectable at 15 and 30 min with average concentrations of 540 and 260 nM, respectively (Figure 7). At the maximum concentration (12 g/kg) at 2 and 8 h following administration, some of the rats displayed slightly reduced activity and a hunched posture. These observations, however, normalized at 10 h following administration. At the lower doses (1.3 g/kg and 4.1 g/kg), normal behavior was observed at all time points. No signs of toxicity or deviation from normal behavior were observed 10 h following administration for any of the doses. Thus, according to our data, LaKe appears well tolerated. In accordance with the in vitro assays, the compound is rapidly metabolized and, consequently, results in elevated lactate and BHB levels already after 15 min.

Figure 7 Extended time (8 h) and dose-dependent pharmacokinetics of LaKe. Data are mean ± SD (N = 6).

LaKe Modulates Plasma Levels of Free Fatty Acids and N-L-Lactoyl-phenylalanine

Given that LaKe allows for the controlled increase of BHB and lactate levels in vivo, ingestion of the compound will naturally impact other biological parameters that either respond to or depend on BHB/lactate levels. Toward this end, we confirmed that LaKe (4.5 g/kg) afforded a decrease in plasma free fatty acids (FFA)52,53 compared to vehicle control from 15 min until 105 min. In this short-term experiment, we observed a trend toward increasing levels of FFA in the vehicle-treated samples compared to baseline (significant at 90 min), which we attribute to fasting of the anesthetized rats, which would naturally lead to lipase activation in adipose tissue and FFA release. On this background, LaKe still suppressed FFA levels with a maximum effect >40% at the 75 min time point. Furthermore, LaKe resulted in an increase in the amino acid-derived metabolite N-L-lactoyl-phenylalanine (Lac-Phe), which was recently identified to suppress feeding and obesity in rats16 and has been found to increase following metformin-treatment of type 2 diabetes in humans (Figure 8).54

Figure 8 Assessment of plasma levels of free fatty acids (FFA) and N-L-lactoyl-phenyalanine (Lac-Phe) following oral administration of LaKe (4.5 g/kg) in rats. Data are mean ± SD. For FFA (N = 8 in each group). For Lac-Phe (N = 8 in LaKe group; N = 2 in control group). ns = nonsignificant; * P < 0.05; ** P < 0.01.

In this study, we have demonstrated a novel, low-molecular-weight ester that allows efficient supplementation of (S)-lactate and (R)-beta-hydroxybutyrate following oral administration in rats. The plasma levels obtained mirror those typically observed following fasting (BHB) and during physical activity (lactate), thereby mimicking a subset of the physiological responses triggered by strenuous exercise.55 These initial experiments indicate that LaKe is well-tolerated. We furthermore demonstrate that LaKe ingestion leads to lower levels of plasma free fatty acids (FFA) compared to the vehicle control and, conversely, to an increase in the appetite-suppressing peptide hormone N-L-lactoyl-phenylalanine (Lac-Phe). Overall, these results suggest that LaKe is an excellent candidate molecule for achieving controlled, systematic elevation of plasma levels of lactate and ketone bodies and may trigger the biological responses associated with these metabolites. Future studies will provide deeper investigations of the cardiometabolic, including broader hormone panels, and cardiovascular and neurological effects of LaKe supplementation. Further studies into the absolute bioavailability of LaKe-derived (S)-lactate and BHB, using tracers, will also be of interest.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jafc.4c04849.Detailed experimental descriptions related to synthetic chemistry, stability data for LaKe upon storage, spectroscopic data on final compounds and intermediates, detailed experimental protocols for in vitro and in vivo pharmacokinetics and associated analyses, and copies of NMR spectra (PDF)

Supplementary Material

jf4c04849_si_001.pdf

The authors acknowledge funding from the Novo Nordisk Foundation (grants NNF21OC0069002 and NNF19OC0054782).

The authors declare the following competing financial interest(s): R.N.O., J.M.S, J.H., R.N., N.M., M.J., and T.B.P. are inventors on a patent related to LaKe. N.M., M.J., and T.B.P. are co-founders and shareholders in Mmimetika Biosciences ApS that hold the commercial rights to exploit this patent.

Acknowledgments

The authors acknowledge Tingting Ruan and colleagues (WuXi AppTec, China) for in vitro ADME and PK studies. The authors acknowledge Anders Lohse from NCK A/S (Farum, Denmark) for chemoenzymatic synthesis and stability studies of LaKe.

Abbreviations

BDNF brain-derived neurotrophic factor

BHB beta-hydroxybutyrate

DIPEA N,N-diisopropylethylamine

FFA free fatty acids

GLP-1 glucagon-like peptide 1

HCAR1 hydroxycarboxylic acid receptor 1

HCAR2 hydroxycarboxylic acid receptor 2

Lac-Phe N-L-lactoyl-phenylalanine

LEAP2 liver-expressed antimicrobial peptide 2

SGF simulated gastric fluid.

SIF simulated intestinal fluid

TBS tert-butyldimethylsilyl

THF tetrahydrofuran

TBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate

VEGF vascular endothelial growth factor
==== Refs
References

Nayor M. ; Shah R. V. ; Miller P. E. ; Blodgett J. B. ; Tanguay M. ; Pico A. R. ; Murthy V. L. ; Malhotra R. ; Houstis N. E. ; Deik A. ; et al. Metabolic Insights into the Immediate Response to Exercise in the Middle-Aged Community. Circulation 2020, 142 , 1905–1924. 10.1161/CIRCULATIONAHA.120.050281.32927962
Robbins J. M. ; Rao P. ; Deng S. ; Keyes M. J. ; Tahir U. A. ; Katz D. H. ; Beltran P. M. J. ; Marchildon F. ; Barber J. L. ; Peterson B. ; et al. Plasma proteomic changes in response to exercise training are associated with cardiorespiratory fitness adaptations. JCI Insight 2023, 8 , e165867 10.1172/jci.insight.165867.37036009
Amar D. ; Lindholm M. E. ; Norrbom J. ; Wheeler M. T. ; Rivas M. A. ; Ashley E. A. Time Trajectories in the Transcriptomic Response to Exercise - A Meta-analysis. Nat. Commun. 2021, 12 , 3471 10.1038/s41467-021-23579-x.34108459
Wei W. ; Riley N. M. ; Lyu X. ; Shen X. ; Guo J. ; Raun S. H. ; Zhao M. ; Moya-Garzon M. D. ; Basu H. ; Tung A. S.-H. ; et al. Organism-wide, Cell-type-specific Secretome Mapping of Exercise Training in Mice. Cell Metab. 2023, 35 , 1261–1279.e11. 10.1016/j.cmet.2023.04.011.37141889
Morville T. ; Sahl R. E. ; Moritz T. ; Helge J. W. ; Clemmensen C. Plasma Metabolome Profiling of Resistance Exercise and Endurance Exercise in Humans. Cell Rep. 2020, 33 , 108554 10.1016/j.celrep.2020.108554.33378671
Rennie M. J. ; Jennett S. ; Johnson R. H. The Metabolic Effects of Strenuous Exercise: A Comparison Between Untrained Subjects and Racing Cyclists. Q. J. Exp. Physiol. 1974, 59 , 201–212. 10.1113/expphysiol.1974.sp002262.4495154
Schranner D. ; Kastenmüller G. ; Schönfelder M. ; Römisch-Margl W. ; Wackerhage H. Metabolite Concentration Changes in Humans After a Bout of Exercise: A Systematic Review of Exercise Metabolomics Studies. Sports Med. Open. 2020, 6 , 11 10.1186/s40798-020-0238-4.32040782
Rabinowitz J. D. ; Enerbäck S. Lactate: The Ugly Duckling of Energy Metabolism. Nat. Metab. 2020, 2 , 566–571. 10.1038/s42255-020-0243-4.32694798
Brooks G. A. ; Arevalo J. A. ; Osmond A. D. ; Leija R. G. ; Curl C. C. ; Tovar A. P. Lactate in Contemporary Biology: A Phoenix Risen. J. Physiol. 2022, 600 , 1229–1251. 10.1113/JP280955.33566386
Brooks G. A. ; Osmond A. D. ; Arevalo J. A. ; Duong J. J. ; Curl C. C. ; Moreno-Santillan D. D. ; Leija R. G. Lactate as a Myokine and Exerkine: Drivers and Signals of Physiology and Metabolism. J. Appl. Physiol. 2023, 134 , 529–548. 10.1152/japplphysiol.00497.2022.36633863
Brooks G. A. ; Osmond A. D. ; Arevalo J. A. ; Curl C. C. ; Duong J. J. ; Horning M. A. ; Moreno Santillan D. D. ; Leija R. G. Lactate as a Major Myokine and Exerkine. Nat. Rev. Endocrinol. 2022, 18 , 712 10.1038/s41574-022-00724-0.35915256
Lee S. ; Choi Y. ; Jeong E. ; Park J. ; Kim J. ; Tanaka M. ; Choi J. Physiological Significance of Elevated Levels of Lactate by Exercise Training in the Brain and Body. J. Biosci. Bioeng. 2023, 135 , 167–175. 10.1016/j.jbiosc.2022.12.001.36681523
Brooks G. A. The Science and Translation of Lactate Shuttle Theory. Cell Metab. 2018, 27 , 757–785. 10.1016/j.cmet.2018.03.008.29617642
Schilperoort M. ; Ngai D. ; Katerelos M. ; Power D. A. ; Tabas I. PFKFB2-mediated Glycolysis Promotes Lactate-driven Continual Efferocytosis by Macrophages. Nat. Metab. 2023, 5 , 431–444. 10.1038/s42255-023-00736-8.36797420
Ivashkiv L. B. The hypoxia–lactate axis tempers inflammation. Nat. Rev. Immunol. 2020, 20 , 85–86. 10.1038/s41577-019-0259-8.31819164
Li V. L. ; He Y. ; Contrepois K. ; Liu H. ; Kim J. T. ; Wiggerhorn A. L. ; Tanzo J. T. ; Tung A. S.-H. ; Luy X. ; Zushin P.-J. H. ; et al. An Exercise-inducible Metabolite that Suppresses Feeding and Obesity. Nature 2022, 606 , 785–790. 10.1038/s41586-022-04828-5.35705806
Gibbons T. D. ; Cotter J. D. ; Ainslie P. N. ; Abraham W. C. ; Mockett B. G. ; Campbell H. A. ; Jones E. M. W. ; Jenkins E. J. ; Thomas K. N. Fasting for 20 h Does Not Affect Exercise-induced Increases in Circulating BDNF in Humans. J. Physiol. 2023, 601 , 2121–2137. 10.1113/JP283582.36631068
Schiffer T. ; Schulte S. ; Sperlich B. ; Achtzehn S. ; Fricke H. ; Strüder H. K. Lactate infusion at rest increases BDNF blood concentration in humans. Neurosci. Lett. 2011, 488 , 234–237. 10.1016/j.neulet.2010.11.035.21094220
Morland C. ; Andersson K. A. ; Haugen Ø. P. ; Hadzic A. ; Kleppa L. ; Gille A. ; Rinholm J. E. ; Palibrik V. ; Diget E. H. ; Kennedy L. H. ; et al. Exercise Induces Cerebral VEGF and Angiogenesis via the Lactate Receptor HCAR1. Nat. Commun. 2017, 8 , 15557 10.1038/ncomms15557.28534495
Nalos M. ; Leverve X. ; Huang S. ; Weisbrodt L. ; Parkin R. ; Seppelt I. ; Ting I. ; Mclean A. Half-molar Sodium Lactate Infusion Improves Cardiac Performance in Acute Heart Failure: A Pilot Randomised Controlled Clinical Trial. Crit. Care 2014, 18 , R48 10.1186/cc13793.24666826
Pedersen M. G. B. ; Lauritzen E. S. ; Svart M. V. ; Støy J. ; Søndergaard E. ; Thomsen H. H. ; Kampmann U. ; Bjerre M. ; Jessen N. ; Møller N. ; Rittig N. Nutrient Sensing: LEAP2 Concentration in Response to Fasting, Glucose, Lactate, and β-Hydroxybutyrate in Healthy Young Males. Am. J. Clin. Nutr. 2023, 118 , 1091–1098. 10.1016/j.ajcnut.2023.10.007.37844838
Pedersen M. G. B. ; Søndergaard E. ; Nielsen C. B. ; Johannsen M. ; Gormsen L. C. ; Møller N. ; Jessen N. ; Rittig N. Oral Lactate Slows Gastric Emptying and Suppresses Appetite in Young Males. Clin. Nutr. 2022, 41 , 517–525. 10.1016/j.clnu.2021.12.032.35016146
Yao Z. ; Yan Y. ; Zheng X. ; Wang M. ; Zhang H. ; Li H. ; Chen W. Dietary Lactate Supplementation Protects against Obesity by Promoting Adipose Browning in Mice. J. Agric. Food Chem. 2020, 68 , 14841–14849. 10.1021/acs.jafc.0c05899.33284607
Evans M. ; Cogan K. E. ; Egan B. Metabolism of Ketone Bodies During Exercise and Training: Physiological Basis for Exogenous Supplementation. J. Physiol. 2017, 595 , 2857–2871. 10.1113/JP273185.27861911
Møller N. Ketone Body, 3-Hydroxybutyrate: Minor Metabolite - Major Medical Manifestations. J. Clin. Endocrinol. Metab. 2020, 105 , 2884–2892. 10.1210/clinem/dgaa370.
Kolb H. ; Kempf K. ; Röhling M. ; Lenzen-Schulte M. ; Schloot N. C. ; Martin S. Ketone Bodies: From Enemy to Friend and Guardian Angel. BMC Med. 2021, 19 , 313 10.1186/s12916-021-02185-0.34879839
Newman J. C. ; Verdin E. Ketone Bodies as Signaling Metabolites. Trends Endocrinol. Metab. 2014, 25 , 42–52. 10.1016/j.tem.2013.09.002.24140022
Zhang N. ; Liu C. ; Jin L. ; Zhang R. ; Wang T. ; Wang Q. ; Chen J. ; Yang F. ; Siebert H.-C. ; Zheng X. Ketogenic Diet Elicits Antitumor Properties through Inducing Oxidative Stress, Inhibiting MMP-9 Expression, and Rebalancing M1/M2 Tumor-Associated Macrophage Phenotype in a Mouse Model of Colon Cancer. J. Agric. Food Chem. 2020, 68 , 11182–11196. 10.1021/acs.jafc.0c04041.32786841
Puchalska P. ; Crawford P. A. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017, 25 , 262–284. 10.1016/j.cmet.2016.12.022.28178565
Wang J.-H. ; Guo L. ; Wang S. ; Yu N.-W. ; Guo F.-Q. The Potential Pharmacological Mechanisms of β-Hydroxybutyrate for Improving Cognitive Functions. Curr. Opin. Pharmacol. 2022, 62 , 15–22. 10.1016/j.coph.2021.10.005.34891124
Rittig N. ; Svart M. ; Thomsen H. H. ; Vestergaard E. T. ; Rehfeld J. F. ; Hartmann B. ; Holst J. J. ; Johannsen M. ; Møller N. ; Jessen N. Oral D/L-3-Hydroxybutyrate Stimulates Cholecystokinin and Insulin Secretion and Slows Gastric Emptying in Healthy Males. J. Clin. Endocrinol. Metab. 2020, 105 , e3597–e3605. 10.1210/clinem/dgaa483.
Berg-Hansen K. ; Christensen K. H. ; Gopalasingam N. ; Nielsen R. ; Eiskjær H. ; Møller N. ; Birkelund T. ; Christensen S. ; Wiggers H. Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock: A Randomized, Controlled, Double-Blind Trial. JACC: Heart Failure 2023, 11 , 1337–1347. 10.1016/j.jchf.2023.05.029.37452805
Hørsdal O. K. ; Moeslund N. ; Berg-Hansen K. ; Nielsen R. ; Møller N. ; Eiskjær H. ; Wiggers H. ; Gopalasingam N. Lactate infusion elevates cardiac output through increased heart rate and decreased vascular resistance: a randomised, blinded, crossover trial in a healthy porcine model. J. Transl. Med. 2024, 22 , 285 10.1186/s12967-024-05064-3.38493167
Deemer S. E. ; Plaisance E. P. ; Martins C. Impact of ketosis on appetite regulation-a review. Nutr. Res. (N.Y.) 2020, 77 , 1–11. 10.1016/j.nutres.2020.02.010.
Omori N. E. ; Woo G. H. ; Mansor L. S. Exogenous Ketones and Lactate as a Potential Therapeutic Intervention for Brain Injury and Neurodegenerative Conditions. Front. Hum. Neurosci. 2022, 16 , 846183 10.3389/fnhum.2022.846183.36267349
Plourde G. ; Roumes H. ; Suissa L. ; Hirt L. ; Doche E. ; Pellerin L. ; Bouzier-Sore A.-K. ; Quintard H. Neuroprotective effects of lactate and ketone bodies in acute brain injury Test. J. Cereb. Blood Flow Metab. 2024, 44 , 1078–1088. 10.1177/0271678X241245486.38603600
Carrard A. ; Elsayed M. ; Margineanu M. ; Boury-Jamot B. ; Fragnière L. ; Meylan E. M. ; Petit J.-M. ; Fiumelli H. ; Magistretti P. J. ; Martin J.-L. Peripheral Administration of Lactate Produces Antidepressant-like Effects. Mol. Psychiatry. 2018, 23 , 392–399. 10.1038/mp.2016.179.27752076
Lambertus M. ; Øverberg L. T. ; Andersson K. A. ; Hjelden M. S. ; Hadzic A. ; Haugen Ø. P. ; Storm-Mathisen J. ; Bergersen L. H. ; Geiseler S. ; Morland C. L-lactate Induces Neurogenesis in the Mouse Ventricular-Subventricular Zone via the Lactate Receptor HCA1. Acta Physiol. 2021, 231 , e13587 10.1111/apha.13587.
Yao S. ; Xu M. D. ; Wang Y. ; Zhao S. T. ; Wang J. ; Chen G. F. ; Chen W. B. ; Liu J. ; Huang G. B. ; Sun W. J. ; Zhang Y. Y. ; Hou H. L. ; Li L. ; Sun X. D. Astrocytic Lactate Dehydrogenase A Regulates Neuronal Excitability and Depressive-like Behaviors Through Lactate Homeostasis in Mice. Nat. Commun. 2023, 14 , 729 10.1038/s41467-023-36209-5.36759610
Karnib N. ; El-Ghandour R. ; El Hayek L. ; Nasrallah P. ; Khalifeh M. ; Barmo N. ; Jabre V. ; Ibrahim P. ; Bilen M. ; Stephan J. S. ; Holson E. B. ; Ratan R. R. ; Sleiman S. F. Lactate is an Antidepressant that Mediates Resilience to Stress by Modulating the Hippocampal Levels and Activity of Histone Deacetylases. Neuropsychopharmacology 2019, 44 , 1152–1162. 10.1038/s41386-019-0313-z.30647450
Cunnane S. C. ; Trushina E. ; Morland C. ; Prigione A. ; Casadesus G. ; Andrews Z. B. ; Beal M. F. ; Bergersen L. H. ; Brinton R. D. ; de la Monte S. ; Eckert A. ; Harvey J. ; Jeggo R. ; Jhamandas J. H. ; Kann O. ; la Cour C. M. ; Martin W. F. ; Mithieux G. ; Moreira P. I. ; Murphy M. P. ; Nave K. A. ; Nuriel T. ; Oliet S. H. R. ; Saudou F. ; Mattson M. P. ; Swerdlow R. H. ; Millan M. J. Brain Energy Rescue: An Emerging Therapeutic Concept for Neurodegenerative Disorders of Ageing. Nat. Rev. Drug Discovery 2020, 19 , 609–633. 10.1038/s41573-020-0072-x.32709961
Huang Z. ; Zhang Y. ; Zhou R. ; Yang L. ; Pan H. Lactate as Potential Mediators for Exercise-Induced Positive Effects on Neuroplasticity and Cerebrovascular Plasticity. Front. Physiol. 2021, 12 , 656455 10.3389/fphys.2021.656455.34290615
Cai M. ; Wang H. ; Song H. ; Yang R. ; Wang L. ; Xue X. ; Sun W. ; Hu J. Lactate Is Answerable for Brain Function and Treating Brain Diseases: Energy Substrates and Signal Molecule. Front. Nutr. 2022, 9 , 800901 10.3389/fnut.2022.800901.35571940
Jensen N. J. ; Wodschow H. Z. ; Nilsson M. ; Rungby J. Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases. Int. J. Mol. Sci. 2020, 21 , 8767 10.3390/ijms21228767.33233502
López-Ojeda W. ; Hurley R. A. Ketone Bodies and Brain Metabolism: New Insights and Perspectives for Neurological Diseases. J. Neuropsychiatry Clin. Neurosci. 2023, 35 , 104–109. 10.1176/appi.neuropsych.20230017.37057361
Yang H. ; Shan W. ; Zhu F. ; Wu J. ; Wang Q. Ketone Bodies in Neurological Diseases: Focus on Neuroprotection and Underlying Mechanisms. Front. Neurol. 2019, 10 , 585 10.3389/fneur.2019.00585.31244753
Clarke K. ; Tchabanenko K. ; Pawlosky R. ; Carter E. ; King M. T. ; Musa-Veloso K. ; Ho M. ; Roberts A. ; Robertson J. ; VanItallie T. B. ; Veech R. L. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul. Toxicol. Pharmacol. 2012, 63 , 401–408. 10.1016/j.yrtph.2012.04.008.22561291
Lowder J. ; Fallah S. ; Venditti C. ; Musa-Veloso K. ; Kotlov V. An open-label, acute clinical trial in adults to assess ketone levels, gastrointestinal tolerability, and sleepiness following consumption of (R)-1,3-butanediol (Avela). Front. Physiol. 2023, 14 , 1195702 10.3389/fphys.2023.1195702.37457035
Chen O. ; Blonquist T. M. ; Mah E. ; Sanoshy K. ; Beckman D. ; Nieman K. M. ; Winters B. L. ; Anthony J. C. ; Verdin E. ; Newman J. C. ; Stubbs B. J. Tolerability and Safety of a Novel Ketogenic Ester, Bis-Hexanoyl (R)-1,3-Butanediol: A Randomized Controlled Trial in Healthy Adults. Nutrients 2021, 13 , 2066 10.3390/nu13062066.34208742
Stubbs B. J. ; Cox P. J. ; Kirk T. ; Evans R. D. ; Clarke K. Gastrointestinal Effects of Exogenous Ketone Drinks are Infrequent, Mild, and Vary According to Ketone Compound and Dose. Int. J. Sport Nutr. Exerc. Metab. 2019, 29 , 596–603. 10.1123/ijsnem.2019-0014.31034254
Chandra P. ; Enespa ; Singh R. ; Arora P. K. Microbial lipases and their industrial applications: a comprehensive review. Microb. Cell Fact. 2020, 19 , 169 10.1186/s12934-020-01428-8.32847584
Svart M. ; Rittig N. ; Pedersen S. B. ; Jessen N. ; Møller N. Oral 3-hydroxybutyrate ingestion decreases endogenous glucose production, lipolysis, and hormone-sensitive lipase phosphorylation in adipose tissue in men: a human randomized, controlled, crossover trial. Diabetic Med. 2021, 38 , e14385 10.1111/dme.14385.32794582
Pedersen M. G. B. ; Rittig N. ; Bangshaab M. ; Berg-Hansen K. ; Gopalasingam N. ; Gormsen L. C. ; Søndergaard E. ; Møller N. Effects of exogenous lactate on lipid, protein, and glucose metabolism—a randomized crossover trial in healthy males. Am. J. Physiol. Endocrinol. Metab. 2024, 326 , E443–E453. 10.1152/ajpendo.00301.2023.38324259
Scott B. ; Day E. A. ; O’Brien K. L. ; Scanlan J. ; Cromwell G. ; Scannail A. N. ; McDonnell M. E. ; Finlay D. K. ; Lynch L. Metformin and feeding increase levels of the appetite-suppressing metabolite Lac-Phe in humans. Nat. Metab. 2024, 6 , 651–658. 10.1038/s42255-024-01018-7.38499765
Gubert C. ; Hannan A. J. Exercise mimetics: harnessing the therapeutic effects of physical activity. Nat. Rev. Drug Discovery 2021, 20 , 862–879. 10.1038/s41573-021-00217-1.34103713
